Regenxbio Inc (RGNX)

$13.87 +1.02 (7.94%)
Market Cap 702.14M
Revenue (ttm) 83.33M
Net Income (ttm) -227.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -272.53%
Debt to Equity Ratio 0.00
Volume 604,400
Avg Vol 615,286
Day's Range N/A - N/A
Shares Out 50.62M
Stochastic %K 83%
Beta 1.14
Analysts Strong Sell
Price Target $29.55

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
Zaens
Zaens Dec. 12 at 7:44 PM
$RGNX The pipeline is amazing with a long list … Can’t imagine the share price within the next 3-4 years if all got approved. Could reach 200$ or more
0 · Reply
Cashmoneyt
Cashmoneyt Dec. 12 at 7:39 PM
$RGNX $14 😎
0 · Reply
Zaens
Zaens Dec. 12 at 6:42 PM
$RGNX ❤️
0 · Reply
Cashmoneyt
Cashmoneyt Dec. 12 at 4:32 PM
$RGNX Would be great to end this Friday at over $14.
0 · Reply
Olena
Olena Dec. 9 at 6:59 PM
$RGNX pt $20-25 on approval
1 · Reply
Olena
Olena Dec. 9 at 6:59 PM
$RGNX should statt climbing towards feb 8
1 · Reply
WaveRB77
WaveRB77 Dec. 9 at 5:46 AM
$RGNX Does RGNX just get bought????
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 6 at 12:27 AM
$RGNX Share Price: $13.16 Contract Selected: Jul 17, 2026 $14.0 Calls Buy Zone: $1.40 – $1.73 Target Zone: $2.44 – $2.99 Potential Upside: 65% ROI Time to Expiration: 223 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
buymoremakemore
buymoremakemore Dec. 4 at 4:06 PM
$RGNX My $12.30 cost basis looking real good rn
0 · Reply
Olena
Olena Dec. 4 at 2:59 AM
$RGNX REGENXBIO reported Q3 2025 revenue of $30M, up 25% YoY, driven by its Nippon Shinyaku partnership. Cash reserves rose to $302M, funding operations into early 2027. Key catalysts ahead include RGX-121’s February 2026 PDUFA and RGX-202 pivotal data in Q2 2026, with a BLA filing planned mid-2026.
0 · Reply
Latest News on RGNX
REGENXBIO to Participate in Upcoming Investor Conference

Nov 25, 2025, 7:05 AM EST - 18 days ago

REGENXBIO to Participate in Upcoming Investor Conference

REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:16 PM EST - 5 weeks ago

REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:05 AM EST - 5 weeks ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Oct 30, 2025, 7:05 AM EDT - 6 weeks ago

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Oct 29, 2025, 7:05 AM EDT - 6 weeks ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO to Participate in Upcoming Investor Conferences

Oct 15, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Oct 9, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Oct 6, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

REGENXBIO Announces Presentation at the World Muscle Society

Sep 29, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO Announces Presentation at the World Muscle Society

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Sep 9, 2025, 6:12 AM EDT - 3 months ago

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 2:05 PM EDT - 3 months ago

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Sep 6, 2025, 8:29 AM EDT - 3 months ago

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Sep 5, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Aug 19, 2025, 12:01 PM EDT - 4 months ago

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 18, 2025, 5:00 PM EDT - 4 months ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 9:11 AM EDT - 4 months ago

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Aug 7, 2025, 7:00 AM EDT - 4 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 31, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jul 10, 2025, 11:54 AM EDT - 5 months ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 6, 2025, 4:02 PM EDT - 6 months ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 11:43 AM EDT - 6 months ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 5, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Jun 2, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025, 4:05 PM EDT - 7 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 14, 2025, 7:13 AM EDT - 7 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:07 AM EDT - 7 months ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 13, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 12, 2025, 4:05 PM EDT - 7 months ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

May 8, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Apr 30, 2025, 4:05 PM EDT - 8 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

5 Reasons To Buy Regenxbio Right Now

Mar 26, 2025, 12:31 PM EDT - 9 months ago

5 Reasons To Buy Regenxbio Right Now

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 19, 2025, 9:15 AM EDT - 9 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 6:44 PM EDT - 9 months ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 13, 2025, 4:05 PM EDT - 9 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 10, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Mar 4, 2025, 7:31 AM EST - 10 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 26, 2025, 4:05 PM EST - 10 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Feb 11, 2025, 3:20 PM EST - 10 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 30, 2025, 7:05 AM EST - 11 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

Jan 16, 2025, 4:01 AM EST - 11 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 15, 2025, 3:27 PM EST - 11 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 14, 2025, 5:00 AM EST - 11 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

Jan 13, 2025, 8:31 AM EST - 11 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Dec 6, 2024, 6:29 PM EST - 1 year ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 18, 2024, 7:05 AM EST - 1 year ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 14, 2024, 7:05 AM EST - 1 year ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:16 PM EST - 1 year ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Nov 6, 2024, 4:05 PM EST - 1 year ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31, 2024, 3:38 PM EDT - 1 year ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Zaens
Zaens Dec. 12 at 7:44 PM
$RGNX The pipeline is amazing with a long list … Can’t imagine the share price within the next 3-4 years if all got approved. Could reach 200$ or more
0 · Reply
Cashmoneyt
Cashmoneyt Dec. 12 at 7:39 PM
$RGNX $14 😎
0 · Reply
Zaens
Zaens Dec. 12 at 6:42 PM
$RGNX ❤️
0 · Reply
Cashmoneyt
Cashmoneyt Dec. 12 at 4:32 PM
$RGNX Would be great to end this Friday at over $14.
0 · Reply
Olena
Olena Dec. 9 at 6:59 PM
$RGNX pt $20-25 on approval
1 · Reply
Olena
Olena Dec. 9 at 6:59 PM
$RGNX should statt climbing towards feb 8
1 · Reply
WaveRB77
WaveRB77 Dec. 9 at 5:46 AM
$RGNX Does RGNX just get bought????
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 6 at 12:27 AM
$RGNX Share Price: $13.16 Contract Selected: Jul 17, 2026 $14.0 Calls Buy Zone: $1.40 – $1.73 Target Zone: $2.44 – $2.99 Potential Upside: 65% ROI Time to Expiration: 223 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
buymoremakemore
buymoremakemore Dec. 4 at 4:06 PM
$RGNX My $12.30 cost basis looking real good rn
0 · Reply
Olena
Olena Dec. 4 at 2:59 AM
$RGNX REGENXBIO reported Q3 2025 revenue of $30M, up 25% YoY, driven by its Nippon Shinyaku partnership. Cash reserves rose to $302M, funding operations into early 2027. Key catalysts ahead include RGX-121’s February 2026 PDUFA and RGX-202 pivotal data in Q2 2026, with a BLA filing planned mid-2026.
0 · Reply
Olena
Olena Dec. 4 at 2:39 AM
$RGNX what’s pt if when approved on February 8?
2 · Reply
buymoremakemore
buymoremakemore Dec. 3 at 2:58 PM
$RGNX finished adding to my position. Love end of year discounts. They can only keep this down for so long.
1 · Reply
rando321456
rando321456 Dec. 3 at 2:23 AM
$RGNX Key little tidbit from today's chat is that they are saying early 26 for the first patient dosed in the 2b/3. Seems like they're gonna go from interim to pivotal with fast enrollment. Ideally this trial setup looks like 6 month recruitment to 6 month readout for the 2b to 9-12 month recruitment for the phase 3s and 12 month readout. So if they hustle maybe 2029 approval.
2 · Reply
buymoremakemore
buymoremakemore Dec. 2 at 10:59 PM
$RGNX Buying another 1k tomorrow
1 · Reply
Enodloca
Enodloca Dec. 2 at 8:37 PM
$RGNX wait for it, in a day or two pps will suddenly shoot up a few dollars.
0 · Reply
DarkOrb
DarkOrb Dec. 2 at 6:49 PM
$RGNX Solid conference presentation today. 2026 will be a big year for possible catalysts.
0 · Reply
buymoremakemore
buymoremakemore Dec. 2 at 4:38 PM
$RGNX Bought 4k shares on that dip!! Wish I got in in the $12.15s but happy to be in at $12.30. $15 in January!
0 · Reply
buymoremakemore
buymoremakemore Dec. 2 at 4:16 PM
$RGNX What didnt they like?
1 · Reply
WaveRB77
WaveRB77 Dec. 2 at 2:10 PM
$RGNX awsome fireside chat.This company is ground zero for Gene therapy.From there untra modern manufacturing facilities which the FDA approved already.No dilution needed.This company explodes in 2026.FEBRUARY 8TH IS LIFTOFF.
1 · Reply
Enodloca
Enodloca Dec. 1 at 8:21 PM
$RGNX
1 · Reply
buymoremakemore
buymoremakemore Dec. 1 at 6:17 PM
$RGNX $KURA just when these are at a discount, Im tied up. Just a few more days…
0 · Reply
Olena
Olena Nov. 28 at 10:43 AM
$RGNX going down today
2 · Reply